#TherapeuticAntibody

[govindhtech]

Innovations in Generative AI and Foundation Models

Generative AI in Therapeutic Antibody Development: With the cooperation announced today, Boehringer Ingelheim and IBM will be able to employ IBM’s foundation model technology to find new candidate antibodies for the development of effective treatments.

Boehringer Ingelheim’s Andrew Nixon, Global Head of Biotherapeutics Discovery, said, “We are very excited to collaborate with the research team at IBM, who share our vision of making in silico biologic drug discovery a reality.” “We will create an unparalleled platform for expedited antibody discovery by collaborating with IBM scientists, and I am sure that this will allow Boehringer to create and provide novel treatments for patients with significant unmet needs.”

Boehringer plans to use a pre-trained AI model created by IBM, which will be further refined using additional proprietary data owned by Boehringer. Vice President of Accelerated Discovery at IBM Research Alessandro Curioni stated, “IBM has been at the forefront of creating generative AI models that extend AI’s impact beyond the domain of language.” “We are excited to now enable Boehringer, a pioneer in the creation and production of antibody-based treatments, to leverage IBM’s multimodal foundation model technologies to help quicken Boehringer’s ability to develop new therapeutics.”

Foundational models for the finding of antibodies

Therapeutic antibodies play a key role in the management of numerous illnesses, such as infectious, autoimmune, and cancerous conditions. The identification and creation of therapeutic antibodies encompassing a variety of epitopes continues to be an extremely difficult and time-consuming procedure, even with significant technological advancements.

Researchers from IBM and Boehringer will work together to use in-silico techniques to speed up the antibody discovery process.  New human antibody sequences will be generated in silico using the sequence, structure, and molecular profile data of disease-relevant targets as well as success criteria for therapeutically relevant antibody molecules, such as developability, specificity, and affinity. The efficacy and speed of antibody discovery, as well as the quality of anticipated antibody candidates, are intended to be enhanced by these techniques, which are based on new IBM foundation model technology.

The defined targets are designed with antibody candidates using IBM’s foundation model technologies, which have proven effective in producing biologics and small molecules with relevant target affinities. AI-enhanced simulation is then used to screen the antibody candidates and select and refine the best binders for the target. The antibody candidates will be produced at mini-scales and evaluated experimentally by Boehringer Ingelheim as part of a validation process. Subsequently, the outcomes of the lab trials will be applied to enhance the in-silico techniques through feedback loops.

Boehringer is creating a cutting-edge digital ecosystem to facilitate the acceleration of medication discovery and development and to generate new breakthrough prospects to improve the lives of patients by working with top academic and industry partners.

Generative AI in Therapeutic Antibody Development

Additionally, IBM is using foundation models and Generative AI to speed up the discovery and development of new biologics and small chemicals, and this study is the latest in this endeavor. Earlier in the year, the business’s Generative AI model accurately predicted the physico-chemical characteristics of tiny compounds that resembled drugs. 

Pre-trained models for drug-target interactions and protein-protein interactions are developed using a variety of heterogeneous, publically available data sets by the IBM Biomedical Foundation Model Technologies.  In order to provide newly created proteins and small molecules with the required qualities, the pre-trained models are subsequently refined using particular confidential data belonging to IBM’s partner.

Concerning Boehringer Ingelheim

Innovative treatments that change lives now and for future generations are being developed by Boehringer Ingelheim. As a top biopharmaceutical business focused on research, it adds value through innovation in highly unmet medical needs. Having been family-owned since its founding in 1885, Boehringer Ingelheim adopts a long-term, sustainable viewpoint. The two business groups, Human Pharma and Animal Health, employ more than 53,000 people to service more than 130 markets. Go to www.boehringer-ingelheim.com to learn more.

Regarding IBM

IBM is a top global supplier of Generative AI, hybrid cloud, and consulting services. They assist clients in over 175 countries to acquire a competitive advantage in their respective industries, optimize business processes, cut expenses, and capitalize on insights from their data. IBM’s hybrid cloud platform and Red Hat OpenShift are used by over 4,000 government and business institutions in critical infrastructure domains including financial services, telecommunications, and healthcare to facilitate their digital transformations in a timely, secure, and effective manner.

IBM clients are given open and flexible alternatives by IBM’s ground-breaking advances in artificial intelligence (AI), quantum computing, industry-specific cloud solutions, and consultancy. IBM has a strong history of upholding integrity, openness, accountability, diversity, and customer service.

Read more on Govindhtech.com

[elainaledoyen]

Recombinant monoclonal antibodies are one of the most promising drugs (immunotherapy) for human diseases which include infectious diseases, cancer, and various other diseases. Mammalian cells (CHO, HEK293, PER.6) are primarily being used to produce therapeutic antibodies, except single chain antibodies without PTMs (glycosylation) which are expressed in non-mammalian cells or cell-free expression systems.  Generation of antibody producing stable cell lines is the single most factor for large-scale manufacturing of therapeutic antibodies. There are several critical factors that are associated with generating stable cell lines for expressing therapeutically active recombinant antibodies. These factors include engineering of antibodies, vectors, and mammalian cells.

[nickyhants]

Yasmina Abdiche from Carterra presents "Expanding SPR throughput orders of magnitude to accelerate therapeutic antibody discovery" at Promega UK's 4th Biologics Symposium on 1st October 2019 at the Babraham Institute Book your place on our website (link in bio) . . . #bioassays #labchat #biologics #antibody #therapeuticantibody #antibodydiscovery #antibodyinhibitors #antibodies #immuneoncology #labwork #immunotherapy #LabLife #PhDLife #assays #Babraham #Cambridge #BiologicsSymposium #Promega #PromegaUK #laboratorywork #immunooncology #cancerresearch #oncologyresearch #assays #Carterra https://ift.tt/304QZwT

[elainaledoyen]

Therapeutic antibodies have become an important class of protein drugs for the treatment of numerous human diseases as well as uses in immunoassays. Nearly 100 monoclonal antibody-based drugs have been approved for the treatment of immunologic diseases and cancer. These therapeutic protein antibodies include hybridomas, recombinant antibodies (mAbs), humanized monoclonal antibodies (including chimeric antibodies), glyco-engineered antibodies, Fab fragments, single chain antibodies, single domain antibodies, bispecific/bifunctional antibodies, antibody-drug conjugates (ADC), “antigenized” antibodies, or antibody-fusion proteins. Development of robust, efficient, and cost-effective methods for large-scale purification of therapeutically active antibodies/proteins with homogeneous purity are inevitable for therapeutic antibodies.

[nickyhants]

Join Promega and fellow research scientists from the biologics field at our 4th annual Biologics Symposium at the Babraham Research Campus in Cambridge on 1st October 2019. Learn about the new developments in Promega's bioassay portfolio from one of the directors of R&D, and hear our guest speakers discuss recent advances in therapeutic antibody discovery and development for immuno-oncology. This event was over subscribed last year so register for the Biologics Symposium 2019 today on the events page of our website (link in bio). . . . #LabChat #biologics #bioassays #immunooncology #oncologyresearch #therapeuticantibody #biologicssymposium #bioassay #bioassaydevelopment #Promega #PromegaUK #sciencerandd #research #science #scientists #biology #biologists #ilovescience #instascience #researchers #randd #Lablife #scienceevent #cancerresearch #drugdiscovery #antibodydiscovery #BabrahamResearchCampus #Babraham #Cambridge https://ift.tt/2Z6SQ0r